Half-Year 2022 Financial and Clinical Trials Update
Roche
Tiragolumab (anti-TIGIT, RG6058, MTIG7192A)
Monoclonal antibody targeting the immune checkpoint inhibitor TIGIT
Indication
Phase/study
# of patients
Design
Locally advanced esophageal cancer (EC)
Phase III
SKYSCRAPER-07
N=750
ARM A: Tiragolumab plus Tecentriq
ARM B: Tecentriq plus placebo
ARM C: Placebo plus placebo
"
1L esophageal cancer (EC)
Phase III
SKYSCRAPER-08
N=500
ARM A: Tiragolumab plus Tecentriq plus
cisplatin and paclitaxel
ARM B: Placebo plus placebo plus cisplatin
and paclitaxel
1L recurrent/metastatic PD-L1 positive
squamous cell head and neck carcinoma
(SCCHN)
Phase II
SKYSCRAPER-09
N=120
ARM A: Tiragolumab plus Tecentriq
ARM B: Tecentriq plus placebo
▪ Progression-free survival (A vs C)
◉
Overall survival and progression-free survival
■ Objective response rate
Primary endpoint
■ Overall survival (A vs C, hierarchical, B vs C
hierarchical)
FPI Q3 2020
■ FPI Q1 2021
Status
CT Identifier
NCT04543617
NSCLC-Non-small cell lung cancer; PD-L1-Programmed cell death-ligand 1
"
FPI Q4 2020
Recruitment completed Q4 2021
NCT04540211
■ Recruitment completed Q2 2022
NCT04665843
129
OncologyView entire presentation